Med BioGene Inc.
TSX VENTURE : MBI

Med BioGene Inc.

May 20, 2015 15:28 ET

MBI Appointment of Investor Relations and Business Advisory Consultant and Grant of Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 20, 2015) - Med BioGene Inc. ("MBI" or the "Company") (TSX VENTURE:MBI) is pleased to announce that, subject to regulatory approval, it has engaged Rick Peterson of Peterson Capital to provide investor relations and business advisory services to the Company.

Mr. Peterson has worked at senior roles in leading investment dealers in the Canadian capital markets over the past 25 years, including Midland Walwyn Capital Inc., Merrill Lynch Canada, Yorkton Securities and HSBC Securities. He has significant experience in the venture capital markets, with a wide network of Investment Advisors, institutional salespeople and investment bankers across Canada and in Europe. Mr. Peterson was previously engaged by MBI in the early stages of the development of the GeneFX® Lung commercialization process in securing critical financing for the Company at the time. "I'm thrilled to be joining the Med BioGene team again and helping to develop and execute a capital markets strategy which will benefit every stakeholder in the company," said Mr. Peterson. The Company will pay Mr. Peterson, through his holding company, Peterson Capital, $5,000 per month for a period of up to six months and will issue 300,000 stock options to Mr. Peterson at an exercise price of $0.10 which will vest in four equal tranches over the next twelve months.

The appointment of Mr. Peterson is subject to TSXV acceptance under Policy 3.4 of the TSXV Corporate Finance Manual.

The Company also announces that it has granted 1.4 million stock options to Directors and Senior Officers. All options will be immediately exercisable at an exercise price of $0.10 and will expire on December 31, 2018.

About Med BioGene Inc.

MBI is a life science company based in Vancouver, British Columbia that is currently focused on managing the license and rights to GeneFX Lung™, a prognostic genomic based test procedure. MBI's common shares are listed for trading on the Exchange. For more information, please visit www.medbiogene.com

This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable Canadian and United States legislation. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include those risks set out in the Company's public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release

Contact Information